Top line data: Upadacitinib in Ulcerative colitis
Keynote speaker: Dr Réme Mountifield
Chair: Prof. Paul Bird
Topics discussed:
Benefit-risk profile of upadacitinib for the treatment of ulcerative colitis followed by a cross-disciplinary discussion.
What did you think of the content? (1 min survey)
The views and opinions expressed are those of the individual speaker/speakers and not necessarily those of AbbVie. AbbVie does not endorse the use of unregistered products or products outside of their registered indications. Please refer to the Approved Product Information for licensed instructions. This information is provided to address your specific enquiry and is for your personal reference only. Please note that AbbVie only recommends the use of its products in accordance with the Approved Product Information or Data Sheet.
ABBV-AU-00081-MC October 2022
Copyright © 2022 AbbVie Pty Ltd. Mascot NSW 2020 Australia.
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates.
No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.